development

View All

Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV

Boston Biomedical starts phase III study of Napabucasin Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced dosing of the first patient in CanStem303C, a new global phase III study investigating napabucasin in combination with standard of...

Find More

dengvaxia
Dengvaxia: Boon for Dengue

The recent outbreak of Dengue in Asia has brought forward the threat of mosquito bite into the spotlight again. Dengue is a kind of viral infection caused by mosquito bite, and the disease has now become a threat to about 390 million people, as these many are estimated to be infected each year. This incidence of inf...

Find More

Liquid Biopsy: Revolutionary Technique for Cancer Diagnosis

Clinicians have been conducting biopsies for a long time, for diagnosing and managing cancer, as genetic profile of tumor is analyzed through biopsy. Tissue biopsy is a traditional biopsy technique which is a time consuming and lengthy procedure, and cannot be performed routinely. Liquid Biopsy is a next generation ...

Find More

Delveinsight
Infectious Disease and Vaccines Pipeline Reports

DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports. VISIT OUR WEBSITE Infectious Diseases and Vaccines The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a fi...

Find More